Response to Comments: MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia

This document (A59360) is a response-to-comments notice regarding the MolDX Local Coverage Determination L39356 for molecular testing to detect upper gastrointestinal metaplasia, dysplasia, and neoplasia. It does not itself specify coverage, indications, limitations, or frequency limits; see LCD L39356 for the full policy details. Key administrative dates: comment period 05/26/2022–07/09/2022, notice period begins 03/30/2023, effective 05/14/2023.

"This document is a response-to-comments notice and does not provide coverage criteria; refer to MolDX Local Coverage Determination L39356 for detailed coverage, coding, and medical necessity criter..."

Sign up to see full coverage criteria, indications, and limitations.